Advanced Life Sciences Announces Appointment of Leading Research Scientist to Board of Directors

Woodridge, Ill, May 23, 2001 - Advanced Life Sciences, Inc. announced today the appointment of Israel (Rudi) Rubinstein, M.D. to its Board of Directors. Dr. Rubinstein is a leading research scientist in respiratory medicine at the Cancer Center, University of Illinois at Chicago and in oncology at the VA Chicago Health Care System, West Side Division.

"We are fortunate that a researcher of Dr. Rubinstein's caliber has joined Advanced Life Sciences Board of Directors," said Dr. Sharon W. Ayd, Chief Operating Officer of Advanced Life Sciences. "Rudi Rubinstein is an expert in the fields of oncology and infection research. This, in addition to his strong knowledge of drug development will help us in our choice and development of therapeutic agents in those areas."

Dr. Rubinstein received an M.D. from Hebrew University-Hadassah School of Medicine and completed fellowships in Respiratory Research at the University of Toronto and in Cardiovascular Research at the University of California San Francisco. Dr. Rubinstein is Professor of Medicine and Professor of Pharmaceutics and Pharmacodynamics at the Colleges of Medicine and Pharmacy, respectively, at the University of Illinois at Chicago. He serves on the Editorial Boards of numerous medical journals, is a consultant to the NIH and has received several academic honors and awards. He has published over 140 articles, contributed to six book chapters and holds ten US patents. Dr. Rubinstein is also President and CEO of Hyperpeptide, Inc., a start-up biopharmaceutical company.

Advanced Life Sciences, Inc., based in Woodridge, Illinois ( is a privately held, early-stage pharmaceutical technology development company that discovers and develops therapeutic compounds to fight infection, inflammation and cancer. The company bridges the gap between academic discoveries and pharmaceutical commercialization and focuses on conditions that have significant unmet medical needs in medium sized markets.

# # #